Literature DB >> 33678607

Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.

Edward F McKone1, Cono Ariti2, Abaigeal Jackson3, Anna Zolin4, Siobhán B Carr5, Annalisa Orenti4, Jacqui G van Rens6,7, Lydie Lemonnier8, Milan Macek9, Ruth H Keogh2, Lutz Naehrlich10.   

Abstract

BACKGROUND: Median survival for cystic fibrosis (CF) patients in Europe is unknown and is likely to be influenced by socioeconomic factors. Using the European CF Society Patient Registry (ECFSPR), median survival estimates were obtained for CF patients across Europe and the impact of socioeconomic status on survival was examined.
METHODS: CF subjects known to be alive and in the ECFSPR between 2010 and 2014 were included. Survival curves were estimated using the Kaplan-Meier method. Differences in the survival curves were assessed using the log-rank test. Cox regression was used to estimate the association between socioeconomic factors and the age-specific hazard of death, with adjustment for sex, age at diagnosis, CF transmembrane conductance regulator (CFTR) genotype and transplant status.
RESULTS: The final analysis included 13 countries with 31 987 subjects (135 833 person-years of follow-up) and 1435 deaths. Median survival age for these patients in the ECFSPR was 51.7 (95% CI 50.0-53.4) years. After adjusting for potential confounders age at diagnosis, sex, CFTR genotype and transplant status, there remained strong evidence of an association between socioeconomic factors and mortality (p<0.001). Countries in the highest third of healthcare spending had a 46% lower hazard of mortality (HR 0.54, 95% CI 0.45-0.64) than countries in the lowest third of healthcare spending.
CONCLUSIONS: Median survival for patients with CF in Europe is comparable to that reported in other jurisdictions and differs by socioeconomic factors.
Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.

Entities:  

Mesh:

Year:  2021        PMID: 33678607     DOI: 10.1183/13993003.02288-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  2 in total

Review 1.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

2.  Consistent Assignment of Risk and Benign Allele at rs2303153 in the CF Modifier Gene SCNN1B in Three Independent F508del-CFTR Homozygous Patient Populations.

Authors:  Frauke Stanke; Tim Becker; Haide Susanne Ismer; Inga Dunsche; Silke Hedtfeld; Julia Kontsendorn; Anna-Maria Dittrich; Burkhard Tümmler
Journal:  Genes (Basel)       Date:  2021-09-29       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.